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Earn CME credits at http://
cme.ctsnetjournals.orgTackground: The accuracy of restaging in patients with stage IIIa non–small cell
ung cancer after neoadjuvant chemoradiotherapy is unknown.
ethods: A prospective trial of patients with biopsy-proven N2 disease who
nderwent initial clinical staging with mediastinoscopy, integrated positron emis-
ion tomography/computed tomography (PET/CT), and CT. Patients then were
linically restaged by the same imaging techniques 4 to 12 weeks after their
nduction chemoradiation therapy and then underwent definitive pathologic staging.
esults: Ninety-three patients had their lymph nodes pathologically restaged. Repeat
ET/CT after neoadjuvant therapy missed residual N2 disease in 13/65 (20%) patients
nd falsely suggested it in 7 of 28 (25%). It was more accurate than repeat CT for
estaging at all pathologic stages (stage 0, 92% vs 39%, P  .03; and stage I 89% vs
6%, P .04). When the maximum standardized uptake value of the primary tumor is
ecreased by 75% or more, it is highly likely (likelihood ratio,LR, 6.1) the patient is
complete responder; when it decreased by 55% or more, it is highly likely (LR, 9.1)
he patient is a partial responder. When the maximum standardized uptake value of the
2 node initially involved with metastatic cancer is decreased by more than 50%, it is
ighly likely (LR, 7.9) the node is now benign.
onclusion: Repeat integrated PET/CT is superior to repeat CT for the restaging of
atients with stage IIIa non–small cell lung cancer. The percent decrease in the
aximum standardized uptake value of the primary and of the involved lymph node
s predictive of pathology; however, nodal biopsies are required since a persistently
igh maximum standardized uptake value does not equate to residual cancer.
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G
TSurgical resection in patients with stage IIIa N2
NSCLC usually is reserved for those who have had
their nodes downstaged after neoadjuvant therapy.
owever, clinical restaging in these patients often is mis-
eading. Mediastinoscopy, which is used most frequently to
rove N2 disease, is not commonly repeated. Repeat medi-
stinoscopy often is inaccurate1,2 and associated with in-
reased risk.2,3 Although endoscopic ultrasonography with
ne-needle aspirate (EUS-FNA) can be repeated safely and
s accurate,4,5 it is not available at most centers. Thus, the
urgeon often is left to restage patients on the basis of repeat
omputed tomography (CT) scans, and repeat integrated
ositron emission tomography/computed tomography (PET/
T) using 2-deoxy-2-18F–fluoro-D-glucose.6-9 In a large pro-
pective study of 383 patients, we showed that integrated
ET/CT is only 67% accurate in staging patients who never
eceived neoadjuvant therapy.10 Patients who received neo-
djuvant therapy were excluded from that trial because of
heir participation in this prospective study. The purpose of
his study was twofold: to assess the accuracy of repeat
ntegrated PET/CT versus repeat CT and to evaluate the
hange in the maxSUV of the primary tumor and of the
nvolved mediastinal lymph node after neoadjuvant chemo-
adiotherapy in patients with stage IIIa NSCLC.
ethods
ntry Criterion
etween September 2002 and August 2004, all patients with
SCLC who presented to one surgeon (R.J.C.) and who underwent
ntegrated PET/CT at our institution, underwent a CT scan, had
iopsy-proven N2 disease by mediastinoscopy, and received che-
oradiotherapy were eligible to participate in this study. Medias-
inoscopy before neoadjuvant therapy was required for entry into
his study to rule out N3 disease. Patients were excluded if they
ere younger than 19 years, had a history of type 1 diabetes, or
ad N3 disease. All suspicious sites of nodal or metastatic disease
uggested by PET/CT (maxSUV  2.5) and CT scan were inves-
igated. All patients received carboplatinum-based chemotherapy
nd radiotherapy. The repeat PET/CT and CT scan were performed
o sooner than 4 weeks and no later than 12 weeks after comple-
ion of the neoadjuvant chemoradiotherapy. All patients were
taged clinically and restaged by using the TNM classification
ystem.11An initial clinical stage (later confirmed to be N2 after
iopsy) was assigned for each patient on the basis of the integrated
ET/CT scan, which was read by a nuclear radiologist and on the
asis of the CT scan, which was read by a chest radiologist. After
ompletion of the therapy a post-therapy pathologic stage was
etermined by repeat biopsy or resection.
adiologic Imaging
oth the initial and the repeat PET/CT were performed on an
ntegrated PET/CT scanner (GE Discovery LS PET/CT Scan-
er; General Electric, Milwaukee, Wis). Patients were asked to
ast for 4 hours and then subsequently received 555 MBq (15
Ci) of fluorodeoxyglucose (FDG) intravenously, followed by
ET after 1 hour. The scanning time for emission PET was 5 d
230 The Journal of Thoracic and Cardiovascular Surgery ● Juninutes per bed position. Iterative reconstruction with CT at-
enuation correction was performed. In addition, the most recent
T scan of the chest also was available for visual correlation.
he maxSUV of the primary and each suspicious lymph node
tation was calculated and determined by drawing regions of
nterest on the attenuation-corrected FDG-PET images around it
s described previously.12
rocedures/Staging
atients were staged meticulously. All nodal sites (N2 and N3)
ith a maxSUV of 2.5 or greater were biopsied before pulmonary
esection. Mediastinoscopy, which was performed on all patients,
as used to biopsy suspicious lymph nodes in the 2R, 4R, 2L, 4L
paratracheal), and 7 (subcarinal) stations; transesophageal EUS-
NA was used to biopsy nodes in the 5 stations (posterior aorto-
ulmonary window), 7 (subcarinal), 8 (periesophageal), and 9
inferior pulmonary ligament nodes). EUS-FNA was performed
nly if the PET/CT or the CT suggested metastatic cancer in the 5,
, 7, 8, or 9 stations. All metastatic (M1) sites were investigated
urther with biopsies and/or appropriate tests. Figure 1 depicts the
urrent restaging algorithm used. EUS was performed by a single
Abbreviations and Acronyms
EUS-FNA endoscopic ultrasonography with fine-
needle aspirate
FDG  fluorodeoxyglucose
MRI magnetic resonance imaging
maxSUV maximum standardized uptake value
NSCLC  non–small cell lung cancer
PET/CT  positron emission tomography/computed
tomography
ROC  receiver operator characteristic
igure 1. Staging algorithm for patients with suspected N2
isease.
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TSxperienced endosonographer as described previously.13 In gen-
ral, targets provided by PET/CT and/or CT underwent a biopsy;
owever, if EUS did not identify any anatomic structure for a
iopsy, FNA was not performed.
Patients with suspected M1 disease in the liver, adrenal, or
ontralateral lung underwent definitive biopsy to prove or disprove
1 cancer. If the bone or brain was suspected to harbor metasta-
es, magnetic resonance imaging (MRI) was considered the stan-
ard reference. If patients had biopsy-proven N3 or M1 disease,
he stage was recorded but not entered in this study. Only those
ith biopsy-proven N2 disease were eligible for this study. Patho-
ogic review was performed via standard techniques, and immu-
ohistochemical staining was employed when appropriate. The
athologic stage was assessed by using the international staging
ystem.11
A patient was defined as having unsuspected N2 disease in this
tudy if neither the repeat PET/CT nor the repeat CT suggested any
ancer remained in any of the N2 nodes but the patient had
athologic proof of metastatic NSCLC cancer in at least one N2
ode. Residual N2 disease was defined as persistent, biopsy-
roven NSCLC in an N2 lymph node after completion of chemo-
adiotherapy in the same node that was proven initially to harbor
ancer. The University of Alabama at Birmingham’s institutional
eview board approved both the electronic prospective database
sed for this study and this prospective trial.
tatistical Analysis
ccuracy was determined for repeat PET/CT and CT by using the
athology results as the gold standard. The optimal percentage of
ecrease in maxSUV that was related to the likelihood of having a
esponse to neoadjuvant therapy was determined with the use of
eceiver operator characteristics (ROC) curve analysis. The opti-
al cutoff point was the percentage of decrease that yielded
inimal false-positive and false-negative results. The C-index also
s reported (an area of 0.5 indicates no predictive discrimination,
Figure 2. Outcomes of the 128 patients withnd an area of 1.0 indicates perfect separation of patients with d
The Journal of Thoracicifferent outcomes14). Analysis was performed with SAS 9.0 (SAS
nstitute, Cary, NC).
esults
here were 128 patients (84 men) who presented with
iopsy-proven N2 disease. Ninety-three of these patients
ere restaged pathologically after neoadjuvant chemoradio-
herapy (Figure 2). The types of tumor, procedures used to
rove N2 disease, and distribution of N2 disease are shown
n Table 1. The pathologic stage after the completion of
eoadjuvant therapy also is shown in Table 1. The accuracy
or assessment of pathologic stage by PET/CT and CT was
2% versus 39% (P  .03) for stage 0, 89% versus 36%
P  .04) for stage I, 85% versus 83% (P  .05) for stage
I, 69% versus 67% (P  .05) for stage III, and 85% versus
0% (P  .05) for stage IV.
Figure 2 shows the outcome of patients eligible for this
tudy. Table 2 depicts the distribution of the unsuspected N2
isease in the 13 patients who were staged clinically as N2
egative on PET/CT but had pathologically proven N2 disease
false negatives). The most common locations for unsus-
ected N2 disease were the number 7 lymph node station (6
atients), the number 6 lymph nodes (6 patients), and the
umber 5 lymph node station (3 patients).
Table 3 depicts the decrease in the maxSUV of the
rimary tumor on the basis of the pathologic stage. Patients
ho were complete responders had the greatest median
ecrease in their maxSUV (100%) of the primary tumor.
hose who were downstaged and were partial responders
were N2 negative but still had surviving cancer cells in the
rimary resected tumor) had a median decrease of 68%
P  .01), and those who had residual N2 disease had a
y-proven N2 disease eligible for this study.biopsecrease of only 32% (P  .001).
and Cardiovascular Surgery ● Volume 131, Number 6 1231
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G
TSTable 4 depicts the change in the maxSUV of the lymph
ode initially involved with biopsy-proven cancer after neo-
djuvant therapy. It shows a 87% decrease in the 59 patients
hose nodes were rendered benign, compared with only a
2% decrease in the 34 patients whose nodes harbored
esidual disease (P  .02). Figure 3 depicts the change in
he maxSUV stratified by different lymph node stations.
he greatest fall in the maxSUV occurred in the paratra-
heal (2R and 4R) nodes, compared with the aortopulmo-
ABLE 1. Patient characteristics
atients who initially presented with
2 or N3 disease 128 patients
edian age (range) (y) 67 (34-78)
ender
Male 84
Female 44
istology
Squamous cell carcinoma 33
Adenocarcinoma 48
Bronchoalveolar carcinoma 9
Neuroendocrine 5
Carcinoid 9
Other type of, mixed, or
nonspecified NSCLC
24
rocedures used to document N2
disease*
Mediastinoscopy 128
EUS-FNA 32
Left VATS biopsy 9
Other (Chamberlin) 1
istribution of initial N2 disease
2R, 2L, 4R, or 4L 72
5 or 6 25
7, 8, or 9 31
ean duration between
neoadjuvant therapy and
restaging
5.9 wk (range, 4.1-10.3 wk)
estaging information 93 patients
athologic stage after
neoadjuvant therapy†
0 14
I 22
II 15
III 37
IV 5
o. of patients found to have
unsuspected N2 disease
after pathologic restaging or
resection
13 (14%)
US-FNA, Endoscopic ultrasonography with fine-needle aspirate; NSCLC,
on–small cell lung cancer; VATS, video-assisted thoracic surgery. *Some
atients had 1 procedure. †Excludes patients who were not pathologi-
ally restaged.ary nodes (5 and 6) and the subcarinal node (7). s
232 The Journal of Thoracic and Cardiovascular Surgery ● JunROC curve analysis, as seen in Figure 4, A, demonstrated
n optimal decrease in the maxSUV of 75% or more (LR,
.1) to be indicative of a complete responder. Similarly, a
ecrease in the maxSUV of 55% or more (LR, 9.1)
redicted a patient as a partial responder, as shown in Figure
. The most accurate cutoff point to predict a lymph node’s
omplete response was a fall in the maxSUV of the node of
0% (LR, 7.9), as shown in Figure 4, B. When the data
as stratified by specific lymph node stations (stations
 4, compared with stations 5  6, and with station 7) a
maller decrease in the maxSUV of the nodes in stations 2
nd 4 was required to predict downstaging than that seen for
he other stations (40%, LR, 7.1; 50%, LR, 4.9; and
0%, LR, 5.1, respectively). The percentage of decrease
n maxSUV was predicted better at the 2  4 lymph node
tations (C  0.84), compared with the 5  6 (C  0.68)
nd 7 stations (C  0.72).
ABLE 2. The distribution of unsuspected N2 disease after
estaging on the basis of PET/CT*
linical stage by
ET/CT after
eoadjuvant
herapy
No. of
patients
No. of patients
with unsuspected
N2 disease
Location of
unsuspected N2
disease
Nodes
No. of
patients
tage 0 12 1 (8.3%) 6, 7, and 9 1
tage I 22 5 (23%) 6 2
7 1
2R and 4R 1
7 and 8 1
tage II 14 5 (36%) 5 and 6 1
7 3
8 1
tage III 33 1 (3%) 5 1
tage IV 12 1 (8.3%) 5 and 6 1
ET/CT, Positron emission tomography/computed tomography. *Excludes
atients who were not pathologically restaged.
ABLE 3. The median percentage decrease in the maxSUV
f the primary on the basis of pathologic restaging
esponse
pathology proven)
No. of
patients*
Median % decrease in the
maxSUV of the
primary tumor (range)
omplete responders
(T0 N0 M0)
14 100% (75%-100%)
ownstaged (excluding
complete responders)
41 68% (2%-100%)
esidual N2 disease 32 32% (5%-82%)
axSUV, Maximum standardized uptake value. *Not all patients had re-
taging of T stage.
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G
TSiscussion
n 2004, 170,000 Americans were diagnosed with NSCLC,
nd almost 1 in 5 patients presented with N2 or stage IIIa
isease.15 Recent studies have shown that patients who are
ownstaged via neoadjuvant therapy and then undergo re-
ection have a significantly longer 5-year survival of 40% to
0%16-18 than do those who have residual N2 disease.19
hus, identification of patients who are N2 negative after
ompletion of their neoadjuvant therapy is a critical com-
onent for patient selection for thoracotomy.
Most patients who are pathologically diagnosed with N2
isease have had mediastinoscopy. Repeat mediastinoscopy
ften is inaccurate1,3 and potentially dangerous, especially
fter chest irradiation. Van Schil and associates2 in 2002
eported on 27 patients who underwent repeat mediastinos-
opy after neoadjuvant therapy and found that 4 of the 16
25%) patients were false negatives. Mateu-Navarro and
ssociates1 in 2000 reported on 24 patients and 5 of the 12
ad false-negative N2 disease. Some surgeons have used
US-FNA to rebiopsy stations 5, 7, 8, and 9, but most
ndosonographers are unable to adequately visualize the
ower paratracheal nodes well.20 Annema and colleagues5 in
003 reported 83% accuracy for repeat EUS-FNA in 19
atients after neoadjuvant chemoradiotherapy. However,
US is available in only a few centers. Thus, the surgeon is
ften left with the clinical stage, as assessed via repeat
ET/CT and CT, to guide him or her. Therefore, we eval-
ated the accuracy of these repeat imaging modalities after
eoadjuvant therapy.
In this prospective study we found that repeat integrated
DG–PET/CT was a better predictor than repeat CT of the
athology at all stages and, thus, of mediastinal nodal dis-
ase. This superiority achieved statistical significance for
hose patients with pathologic stage 0 and I disease. The
ABLE 4. Percentage decrease in the maxSUV of the
iopsy-proven N2-positive lymph node after pathologic
estaging
No. of
patients
Location of initially
involved N2 node Median %
decrease of
maxSUV* (range)Node
No. of
patients
esponder
(N2 ¡ N0)
59 2R and 4R
5 and 6
36
13
87% (2%-100%)
7 16
8 and 9 4
esidual N2
disease
(N2 ¡ N2)
34 2R and 4R
5 and 6
10
12
52% (16%-84%)
7 13
8 and 9 3
axSUV, Maximum standardized uptake value. *P  .02.ccuracy of repeat PET/CT was best for complete respond- s
The Journal of Thoracicrs (92%) and for those with stage I disease (89%); how-
ver, it fell to only 69% for those with persistent stage III
isease. Interestingly, in a parallel study that we performed
with similar methods over the same time span), we found
hat the accuracy of PET/CT in patients who had not had
eoadjuvant therapy was not much better than it was for the
atients in this study who had chemoradiotherapy.10 Reed
nd colleagues21 in a multi-institutional study also showed
he relative inaccuracy of PET/CT in patients with NSCLC.
khurst and colleagues (2002)22 evaluated the efficacy of
epeat FDG-PET in 56 patients who had induction ther-
py and reported a sensitivity of 90% but a specificity of
nly 67%.
Although repeat integrated PET/CT was better than re-
eat CT for the prediction of residual or benign nodal
isease, false negatives and false positives were not infre-
uent (20% and 25%, respectively). Thus, rebiopsy of the
ode, especially if the maxSUV has not fallen significantly,
s mandatory. Some nodes can be rebiopsied with minimally
nvasive techniques such as EUS-FNA or video-assisted
horacoscopy. In this study we found the most common
ocation of unsuspected N2 disease was in the 7 (subcarinal)
ymph node station followed by the 5 (posterior aortopul-
onary) station. Both of these lymph node stations are
ccessible via EUS-FNA. Thus, perhaps EUS-FNA should
e considered in these patients,23-25 as well as in those who
ave not undergone neoadjuvant therapy, to help stage them
y providing tissue. In 2003 we studied dedicated PET (not
ntegrated PET/CT) and found that it was accurate for the
R and 4R nodal stations after neoadjuvant therapy.26 Sim-
larly, in this study, as shown in Figure 3, the change in the
axSUV of the paratracheal lymph nodes is predictive of
athology. This finding is important clinically since this
igure 3. Median percentage of change in the maxSUV of N2
ymph nodes in various stations on the basis of pathologic
esponse.tation is difficult to rebiopsy accurately with minimally
and Cardiovascular Surgery ● Volume 131, Number 6 1233
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G
TSnvasive techniques and, thus, helps guide the decision for
horacotomy. The ideal time to repeat a PET or PET/CT
fter radiotherapy or chemotherapy is unknown; however,
n our experience we find it to be accurate between 4 and 12
eeks. Other studies have reported that a period of less than
weeks between the end of radiation and repeat PET
canning may interfere with test results.27
axSUV Data
he change in the maxSUV continues to be an important
nd a relatively new area of research. In this report we found
hat the change in the maxSUV of the primary tumor was an
ccurate predictor of pathologic response, which mirrors
ur findings in 2004 on 56 patients.28 Ryu and colleagues29
n 2002 had similar findings; however, Port and colleagues30
id not. Our consistent results may be secondary to the fact
hat we required both the initial and the repeat PET/CT to be
erformed on the same scanner with similar techniques.
his approach may afford better comparison. The percent-
ge of change and not the absolute value of the repeat
ET/CT is predictive. When the maxSUV of the primary
umor decreases by 75% or more, it is highly likely (LR,
.1) that the patient is a complete responder. When it
ecreases by 55% or more, it is highly likely (LR, 9.1)
hat the patient is a partial responder.
There is almost no prior literature on the issue of the
hange of the maxSUV of mediastinal nodes. We found that
he change in the maxSUV of the initially involved lymph
ode also was predictive of disease. Although the percent-
ge of decrease in the maxSUV is helpful, especially if it
alls significantly, a persistently high level is not a reason to
Figure 4. A, Receiver operating characteristics (ROC) cu
for complete responders, solid line (C  0.894), and for
at different cutoff points for the change in the maxSUeny a patient a resection; rather, it only provides a target i
234 The Journal of Thoracic and Cardiovascular Surgery ● Junor a biopsy of that node. However, if the maxSUV of a
ode that was initially involved with metastatic cancer
ecreases by 50%, it is highly likely (LR, 7.9) that the
ode has been rendered benign by the neoadjuvant therapy.
his finding represents a powerful way to noninvasively
auge the pathologic characteristics of mediastinal nodes.
The strengths of this study are its prospective study
esign, the meticulous staging, the fact that all patients
nderwent mediastinoscopy, the limitation of confounders
y having all operations performed by the same surgeon, the
act that a complete thoracic lymphadenectomy was used at
he time of thoracotomy, and the use of the maxSUV for the
rimary tumor and the lymph nodes as opposed to the
ess-reproducible mean SUV.28 The limitations of this study
nclude the fact that it was uni-institutional, 28 patients did
ot have pathologic confirmation after restaging, and 3
atients were lost to follow-up.
In conclusion, we found in this prospective study that repeat
ntegrated PET/CT using FDG is superior to repeat CT for the
estaging of patients with N2 stage IIIa NSCLC after neo-
djuvant chemoradiotherapy. This difference achieved sta-
istical significance for those patients with pathologic stage
and I disease. When the maxSUV of the primary tumor
ecreased by 75% or more, it is highly likely that the patient
s a complete responder. When it decreased by 55% or
ore, it is highly likely that the patient is a partial re-
ponder. When the maxSUV of a node that was involved
nitially with metastatic cancer decreased by 50% or more,
t is highly likely that the node has been rendered benign by
he neoadjuvant therapy. A persistently high maxSUV of an
at different cutoff points for the change in the maxSUV
ial responders, dashed line (C  0.905). B, ROC curves
initially involved N2 lymph node (C  0.742).rves
part
V fornitially involved mediastinal node should not be perceived
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G
TSs evidence of residual disease, but rather only as an indi-
ation for a repeat biopsy of the node. These data may help
mprove patient selection for thoracotomy and resection.
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